Screener
Theravance Biopharma TBPH Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
FAQ
- What is Theravance Biopharma's restricted cash?
- Theravance Biopharma (TBPH) reported restricted cash of $836K in Q2 2026.
- How has Theravance Biopharma's restricted cash changed year-over-year?
- Theravance Biopharma's restricted cash decreased by 0.0% year-over-year, from $836K to $836K.
- What is the long-term trend for Theravance Biopharma's restricted cash?
- Over 5 years (2020 to 2025), Theravance Biopharma's restricted cash has grown at a 0.1% compound annual growth rate (CAGR), from $833K to $836K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Theravance Biopharma's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude